R. Nolan Townsend has served as Lexeo Therapeutics Chief Executive Officer and member of the Board of Directors since January 2020. Lexeo Therapeutics is a New York City-based, clinical stage biotechnology company that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic diseases. Prior to Lexeo, Mr. Townsend held roles as President, Pfizer Rare Disease for the North America region and President, Pfizer Rare Disease for the International markets; overseeing overall strategy, the cross functional organization and operating budget in those regions. Mr. Townsend has over a decade of experience with Pfizer first joining the company in Corporate Finance and subsequently in roles of increasing responsibility across Corporate Finance, Corporate Strategy, Operations, Marketing, General Management and Commercial leadership in Pfizer’s New York headquarters, Asia, Africa/Middle East and Europe. Prior to Pfizer, Mr. Townsend worked in the healthcare investment banking group at Lehman Brothers, advising healthcare companies on strategic financing transactions and mergers and acquisitions. Mr. Townsend serves on the Board of Directors of Arbor Biotechnologies and the Biotechnology Innovation Organization (BIO). Mr. Townsend has been appointed to New York City Economic Development Corporation’s Life Sciences Advisory Council and is the Chairman of the Board of Directors of Life Science Cares New York. Mr. Townsend received his Masters in Business Administration from the Harvard Business School and his Bachelor of Arts in Economics from the University of Pennsylvania.